All In Biotech

Drug Trial Radar · NCT03668236

The Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care Trial

Last checked: Nov 20, 2026Latest source record: Feb 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,554 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,554

Actual

Start

Nov 27, 2018

Primary completion

Feb 14, 2022

Study completion Nov 16, 2022

Sponsor

Lead sponsor
Anders Perner, MD, PhDAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Copenhagen University Hospital, Rigshospitalet; Centre for Research in Intensive Care (CRIC); Scandinavian Critical Care Trials Group
First posted
Sep 12, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this trial is to assess patient important benefits and harms of IV fluid restriction vs. standard care fluid therapy in patients with septic shock.

Conditions

  • Septic Shock

Interventions

  • Isotonic crystalloidsDrug

    Types of fluid to be used in both intervention groups: * IV fluids given for circulatory impairment: Only isotonic crystalloids are to be used as per the Scandinavian guideline for fluid resuscitation * Fluids given to substitute overt loss: Isotonic crystalloids are to be used. If large amounts of ascites are tapped, then human albumin may be used * Fluids used for dehydration: Water or isotonic glucose should be used * Fluids used for electrolyte disturbances: Fluids should be chosen to substitute the specific deficiency, including water in the case of severe hypernatremia * Blood products are only to be used on specific indications including severe bleeding, severe anaemia and prophylactic in case of severe coagulopathy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 90-day MortalityTime frame: Day 90 after randomisation

Locations

31 sites in 8 countries. Site status is shown where the registry gives one.

  • University Hospital Brussels (UZB)

    Brussels, Belgium

  • Medical Intensive Care Unit, Fakultni Nemocnice

    Pilsen, Czechia

  • Dept. of Anaesthesia and Intensive Care, Aalborg University Hospital, Denmark.

    Aalborg, Denmark

  • Dept of Intensive Care,Copenhagen University Hospital Rigshospitalet

    Copenhagen, Denmark

  • Dept. of Anaesthesia and Intensive Care, Bispebjerg Hospital

    Copenhagen, Denmark

  • Dept. of Anaesthesia and Intensive Care, Herning Hospital

    Herning, Denmark

  • Dept. of Intensive Care, Hillerød Hospital

    Hillerød, Denmark

  • Dept. of Anaesthesia and Intensive Care, Holbæk Hospital

    Holbæk, Denmark

  • Dept. of Anaesthesia and Intensive Care, Zealand University Hospital Køge

    Køge, Denmark

  • Dept. of Anaesthesia and Intensive Care, Lillebaelt Hospital

    Kolding, Denmark

  • Dept. of Anaesthesia and Intensive Care, Randers Hospital

    Randers, Denmark

  • Dept. of Anaesthesia and Intensive Care, Zealand University Hospital Roskilde

    Roskilde, Denmark

  • Dept. of Anaesthesia and Intensive Care, Viborg Hospital

    Viborg, Denmark

  • Dept. of Intensive Care, Ancona Hospital

    Ancona, Italy

  • Dept. of Intensive Care, Humanitas Research Hospital

    Milan, Italy

  • Humanitas research hospital Bergamo

    Bergamo, Milan, Italy

  • Dept. of Intensive Care, Humanitas Research Hospital Castelanza

    Castellanza, Milan, Italy

  • Dept. of intensive care, Østfold, Kalnes

    Grålum, Norway

  • Dept. of intensive Care, Innlandet Hamar

    Hamar, Norway

  • Dept. of Intensive Care, Oslo University Hospital

    Oslo, Norway

  • Dept. of Intensive Care Medicine, Stavanger

    Stavanger, Norway

  • Dept. of Intensive Care Medicine, St Göran

    Gothenburg, Sweden

  • Dept. of intensive care, Huddinge

    Huddinge, Sweden

  • MIMA Medicinsk intermediärvårdsavdelning

    Huddinge, Sweden

  • Dept. of Intensive Care, Solna

    Solna, Sweden

  • Medical ICU, Karolinska, Södersjukhuset

    Stockholm, Sweden

  • Södersjukhuset

    Stockholm, Sweden

  • Dept. of Intensive Care Medicine Sundsvall Hospital

    Sundsvall, Sweden

  • Dept. of intensive care, Basel

    Basel, Switzerland

  • Dept. of Intensive Care, University Hospital Bern

    Bern, Switzerland

  • Dept. of Intensive Care Unit, Guy's and St. Thomas' Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.